---
title: SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World
nct_id: NCT01390935
overall_status: COMPLETED
sponsor: GlaxoSmithKline
study_type: OBSERVATIONAL
primary_condition: Heart Failure, Congestive
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01390935.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01390935"
ct_last_update_post_date: 2012-11-30
last_seen_at: "2026-05-12T06:47:37.014Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World

**Official Title:** SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real WorldMulticenter, Retrospective Observation Study in Korea

**NCT ID:** [NCT01390935](https://clinicaltrials.gov/study/NCT01390935)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1
- **Lead Sponsor:** GlaxoSmithKline
- **Conditions:** Heart Failure, Congestive
- **Start Date:** 2011-03
- **Completion Date:** 2012-05
- **CT.gov Last Update:** 2012-11-30

## Brief Summary

The purpose of this study is to survey the guideline compliance of the cardiologists in the treatment of systolic heart failure in Korea

## Detailed Description

Major improvement in the medical management of CHF has been achieved in the past decades.

But there is no doubt that prognosis of heart failure patients remains poor. The compliance to the standard treatment can be one of reasons. But very little data concerning this in Korea is available.

## Eligibility

- **Minimum age:** 20 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Subjects admitted to hospital with systolic heart failure(LVEF under 45%) in 2009
* Subjects, age 20 or/and above
* Subjects admitted to hospital (emergency area, to internal medicine or to cardiology wards, CCU or intensive care) with dyspnea and verification of heart failure based on following criteria;
* Symptoms typical of heart failure : breathlessness at rest or on exercise, fatigue, tiredness, ankle swelling and Signs typical of heart failure : tachycardia, tachypnoea, pulmonary rales, pleural effusion, raised jugular venous pressure, peripheral oedema, hepatomegaly
* Objective evidence of a structural or functional abnormality of the heart at rest : cardiomegaly, third heard sound, cardiac murmurs, abnormality on the echocardiogram, raised natriuretic peptide concentration

Exclusion Criteria:

* Subject who expired during hospitalization
```

## Arms

- **systolic heart failure** — EF under 45%

## Interventions

- **guideline adherence** (OTHER) — guideline adherence of physician

## Primary Outcomes

- **Mean of modified Guideline Adherence Indicator(mGAI-3)** _(time frame: 1year)_ — Modified percentage based on each participant's condition

## Secondary Outcomes

- **Percentage of participants with each class drug prescribed** _(time frame: 1year)_
- **Percentage of participants with daily target dose reached** _(time frame: 1year)_
- **Percentage of all cause mortality** _(time frame: 1year)_
- **Percentage of All cause hospitalization** _(time frame: 1year)_
- **Mean of mortality or rehospitalization rate according to mGAI-3** _(time frame: 1year)_

## Locations (1)

- GSK Investigational Site, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.gsk investigational site|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01390935.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01390935*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*